A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
2020-07-04
عنوان الدراسة
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
داعم الدراسة
Novartis
دواء الدراسة
Everolimus
رقم بروتوكول الدراسة
CRAD001N2301
حالة الدراسة
Completed
موقع الدراسة
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。